Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 270

1.

In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.

Bentzien F, Zuzow M, Heald N, Gibson A, Shi Y, Goon L, Yu P, Engst S, Zhang W, Huang D, Zhao L, Vysotskaia V, Chu F, Bautista R, Cancilla B, Lamb P, Joly AH, Yakes FM.

Thyroid. 2013 Dec;23(12):1569-77. doi: 10.1089/thy.2013.0137. Epub 2013 Sep 17.

2.

Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.

Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, Seregni E, Martinetti A, Laccabue D, Zanchi C, Zunino F.

J Natl Cancer Inst. 2004 Jul 7;96(13):1006-14.

PMID:
15240784
3.

Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor.

Grüllich C.

Recent Results Cancer Res. 2014;201:207-14. doi: 10.1007/978-3-642-54490-3_12. Review.

PMID:
24756794
4.

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R.

J Clin Oncol. 2011 Jul 1;29(19):2660-6. doi: 10.1200/JCO.2010.32.4145. Epub 2011 May 23.

5.

A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.

Johanson V, Ahlman H, Bernhardt P, Jansson S, Kölby L, Persson F, Stenman G, Swärd C, Wängberg B, Stridsberg M, Nilsson O.

Endocr Relat Cancer. 2007 Jun;14(2):433-44.

6.

[Cabozantinib: Mechanism of action, efficacy and indications].

Cochin V, Gross-Goupil M, Ravaud A, Godbert Y, Le Moulec S.

Bull Cancer. 2017 May;104(5):393-401. doi: 10.1016/j.bulcan.2017.03.013. Epub 2017 May 3. French.

PMID:
28477875
7.

Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.

Petrangolini G, Cuccuru G, Lanzi C, Tortoreto M, Belluco S, Pratesi G, Cassinelli G, Zunino F.

Biochem Pharmacol. 2006 Aug 14;72(4):405-14. Epub 2006 Jun 6.

PMID:
16756963
8.

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.

Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH.

Mol Cancer Ther. 2011 Dec;10(12):2298-308. doi: 10.1158/1535-7163.MCT-11-0264. Epub 2011 Sep 16.

9.

The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.

Vitagliano D, De Falco V, Tamburrino A, Coluzzi S, Troncone G, Chiappetta G, Ciardiello F, Tortora G, Fagin JA, Ryan AJ, Carlomagno F, Santoro M.

Endocr Relat Cancer. 2010 Nov 30;18(1):1-11. doi: 10.1677/ERC-09-0292. Print 2011 Feb.

10.

The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.

Verbeek HH, Alves MM, de Groot JW, Osinga J, Plukker JT, Links TP, Hofstra RM.

J Clin Endocrinol Metab. 2011 Jun;96(6):E991-5. doi: 10.1210/jc.2010-2381. Epub 2011 Apr 6.

PMID:
21470995
11.

Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.

Krajewska J, Olczyk T, Jarzab B.

Expert Rev Clin Pharmacol. 2016;9(1):69-79. doi: 10.1586/17512433.2016.1102052. Epub 2015 Nov 4. Review.

PMID:
26536165
12.

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.

Schlumberger M, Elisei R, Müller S, Schöffski P, Brose M, Shah M, Licitra L, Krajewska J, Kreissl MC, Niederle B, Cohen EEW, Wirth L, Ali H, Clary DO, Yaron Y, Mangeshkar M, Ball D, Nelkin B, Sherman S.

Ann Oncol. 2017 Nov 1;28(11):2813-2819. doi: 10.1093/annonc/mdx479.

PMID:
29045520
13.

CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.

Strock CJ, Park JI, Rosen M, Dionne C, Ruggeri B, Jones-Bolin S, Denmeade SR, Ball DW, Nelkin BD.

Cancer Res. 2003 Sep 1;63(17):5559-63.

14.

Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.

Drosten M, Stiewe T, Pützer BM.

Hum Gene Ther. 2003 Jul 1;14(10):971-82.

PMID:
12869215
15.

Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition.

Zhang L, Scorsone K, Woodfield SE, Zage PE.

Cancer Chemother Pharmacol. 2015 Nov;76(5):977-87. doi: 10.1007/s00280-015-2871-z. Epub 2015 Sep 25.

PMID:
26407819
16.

Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2.

Navis AC, Bourgonje A, Wesseling P, Wright A, Hendriks W, Verrijp K, van der Laak JA, Heerschap A, Leenders WP.

PLoS One. 2013;8(3):e58262. doi: 10.1371/journal.pone.0058262. Epub 2013 Mar 4.

17.

Anti-tumor activity of motesanib in a medullary thyroid cancer model.

Coxon A, Bready J, Kaufman S, Estrada J, Osgood T, Canon J, Wang L, Radinsky R, Kendall R, Hughes P, Polverino A.

J Endocrinol Invest. 2012 Feb;35(2):181-90. doi: 10.3275/7609. Epub 2011 Mar 21.

PMID:
21422803
18.

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.

Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen EE, Schöffski P, Wirth LJ, Mangeshkar M, Aftab DT, Brose MS.

Cancer. 2016 Dec 15;122(24):3856-3864. doi: 10.1002/cncr.30252. Epub 2016 Aug 15.

19.

Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.

Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ.

Int J Cancer. 2015 Apr 15;136(8):1967-75. doi: 10.1002/ijc.29225. Epub 2014 Sep 29.

20.

XL184 (cabozantinib) for medullary thyroid carcinoma.

Durante C, Russo D, Verrienti A, Filetti S.

Expert Opin Investig Drugs. 2011 Mar;20(3):407-413. doi: 10.1517/13543784.2011.559163. Review.

PMID:
21314233

Supplemental Content

Support Center